Inflazome Co-founder and CEO Matt Cooper Named Cross-Field Highly Cited Researcher by Clarivate Analytics

November 25, 2019

Dublin (IE), Cambridge (UK), Brisbane (AU) | 25 November 2019: Inflazome (, the pioneering inflammasome biotech company developing multiple small molecule drugs that stop harmful inflammation, is pleased to announce that the Company’s Co-founder and Chief Executive Officer, Matt Cooper, has been named a cross-field highly cited researcher by Clarivate Analytics.

Clarivate’s cross-field highly cited research list recognises world-class researchers selected for their exceptional research performance, demonstrated by production of multiple highly cited papers that rank in the top 1 percent by citations for field and year in Web of Science. Each year, Clarivate honours approximately 6,000 researchers worldwide. Clarivate Analytics is a global leader in providing trusted insights and analytics to accelerate the pace of innovation.

Prof Cooper is the Co-founder and Chief Executive Officer of Inflazome and has more than 50 patents and 350 scientific papers. Matt’s work since 2009 has been focused on therapies that block inflammation via modulation of the innate immune system, novel antimicrobials, rapid diagnostics and modulators of the human microbiome.

Clarivate’s full list can be accessed here.


Dr Jeremy Skillington | VP Business Development


FTI Consulting

UK & International | Ciara Martin/Tim Stamper
T: +44 20 37271000

Ireland & International | Jonathan Neilan/Patrick Berkery
T: +353 1 7650800



If you are a member of the media and have a media query please contact:

Contact Us

Speak to us about
a better tomorrow

Contact Us